CE Mark for Mallya device that records key treatment information for diabetic patients

Biocorp announces that Mallya has obtained the CE 0459 mark as medical device class IIb. Mallya is a smart sensor that turns conventional insulin pens into connected devices.

Mallya records the key treatment information (selected dose, date and time of injection) and sends it to a dedicated mobile application. The app also allows the patient user to view a summary report of doses injected over a period of time (up to 90 days). This device allows an automatic recording of the doses injected with the highest accuracy, removing the need of manual logbooks. Mallya fits perfectly with new usages of patients using Continuous Glucose Monitoring Systems or Connected Blood glucose systems.

Mallya is the only device available in its category to be labeled CE medical device, class IIb. The main benefits it offers to patients and health professionals are:- A patented concept, a device tested in several studies, - Ease of installation and use does not disturb the usual use of the pen, - Reliability of information collected and transmitted to the mobile app.

Mallya will be rolled out this fall, supported by BIOCORP commercial partners.